CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.173
EU - Europa 5.856
AS - Asia 4.147
SA - Sud America 619
AF - Africa 324
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.133
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.944
DE - Germania 2.175
SG - Singapore 1.378
CN - Cina 1.242
IT - Italia 1.077
SE - Svezia 830
HK - Hong Kong 710
GB - Regno Unito 562
BR - Brasile 501
BG - Bulgaria 272
AT - Austria 232
RU - Federazione Russa 205
VN - Vietnam 176
CA - Canada 172
TR - Turchia 153
CI - Costa d'Avorio 146
FI - Finlandia 125
IN - India 113
SN - Senegal 104
FR - Francia 89
KR - Corea 80
UA - Ucraina 76
JP - Giappone 75
AR - Argentina 40
BD - Bangladesh 39
MX - Messico 35
CH - Svizzera 33
MA - Marocco 29
NL - Olanda 29
PL - Polonia 29
IQ - Iraq 24
BE - Belgio 23
ZA - Sudafrica 20
ES - Italia 19
IR - Iran 19
VE - Venezuela 17
PK - Pakistan 16
ID - Indonesia 15
CO - Colombia 14
EC - Ecuador 14
PH - Filippine 14
SA - Arabia Saudita 14
LT - Lituania 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 11
AU - Australia 10
IE - Irlanda 10
IL - Israele 10
UY - Uruguay 9
AZ - Azerbaigian 8
MY - Malesia 8
TW - Taiwan 8
CL - Cile 7
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
EE - Estonia 6
EG - Egitto 5
GR - Grecia 5
HU - Ungheria 5
JM - Giamaica 5
JO - Giordania 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
DZ - Algeria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
RO - Romania 4
RS - Serbia 4
TN - Tunisia 4
AL - Albania 3
KE - Kenya 3
LB - Libano 3
NG - Nigeria 3
PT - Portogallo 3
BJ - Benin 2
BY - Bielorussia 2
BZ - Belize 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
PA - Panama 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AO - Angola 1
BH - Bahrain 1
CR - Costa Rica 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 19.122
Salva come PNG Salva come JPEG
Città #
Ashburn 1.030
Dallas 745
Singapore 719
Hong Kong 693
Woodbridge 658
Chandler 580
Santa Clara 541
Fairfield 490
Ann Arbor 403
Milan 359
Houston 314
Beijing 283
Sofia 271
Shanghai 266
New York 254
Seattle 217
Vienna 211
Wilmington 209
Cambridge 182
Los Angeles 165
Abidjan 146
London 139
Princeton 138
Boardman 136
Ottawa 109
Lawrence 106
Munich 106
Dakar 104
Florence 94
Jacksonville 91
Hefei 90
Frankfurt am Main 89
Serra 87
Medford 80
Seoul 74
Pisa 60
Rome 60
Nanjing 59
Izmir 57
Tokyo 57
Istanbul 55
Bremen 52
Dearborn 52
Des Moines 51
Redondo Beach 51
Boulder 50
Dong Ket 49
São Paulo 40
Buffalo 39
San Diego 39
Helsinki 37
Fuzhou 34
Redmond 34
Turku 29
Lancaster 28
Bern 27
Düsseldorf 25
Ho Chi Minh City 25
Redwood City 25
Ogden 24
Denver 23
Brussels 22
Hanoi 21
Montreal 21
San Jose 21
Guangzhou 20
Nanchang 20
Rio de Janeiro 20
Washington 20
Phoenix 19
Brooklyn 18
Quanzhou 18
Toronto 18
Belo Horizonte 17
Casablanca 17
Council Bluffs 17
Warsaw 17
Jiaxing 16
Kunming 16
Orem 16
Chicago 15
Nuremberg 15
San Francisco 15
Atlanta 14
Changsha 14
Stockholm 14
Zhengzhou 14
Boston 13
Chengdu 13
Columbus 13
Jüchen 13
Poplar 13
Pune 13
Baghdad 12
Brasília 11
Johannesburg 11
Ningbo 11
Norwalk 11
Shenyang 11
Tashkent 11
Totale 11.872
Salva come PNG Salva come JPEG
Nome #
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 280
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 270
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 242
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 242
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 237
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 236
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 236
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 230
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 225
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 221
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 221
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 219
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 213
Targeted Therapy in Thyroid Cancer: State of the Art 211
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 209
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 207
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 206
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 203
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 201
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 200
RET point mutations in Thyroid Carcinoma 196
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 196
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 190
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 189
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 185
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 185
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 184
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 183
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 180
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 178
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 177
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 176
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 175
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 174
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 173
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 172
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 170
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 167
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 167
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 163
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 163
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 161
Thyroid consequences of the Chernobyl nuclear accident. 160
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 159
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 159
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 158
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 157
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 157
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 155
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 152
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 152
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 152
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 152
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 151
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 150
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 149
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 149
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 148
null 146
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 144
Thyroid incidentaloma 143
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 143
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 141
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 141
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 140
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 139
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 138
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 136
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 135
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 135
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 133
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 131
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 130
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 129
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 128
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 123
null 122
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 119
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 119
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 117
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 117
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 116
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 115
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 114
null 114
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 114
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 113
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 111
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 110
Totale 16.665
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.574
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.574
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 0 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.598 161 174 220 110 214 283 114 52 28 22 70 150
2024/20254.314 47 154 43 267 483 424 303 218 467 539 422 947
2025/20263.235 405 774 587 470 567 411 21 0 0 0 0 0
Totale 19.391